GNAO1 and Encephalopathy: We conclude that the reported genome-edited mice with the “humanized” fragment of the Gnao1 exon 6 provide a suitable model for preclinical safety studies of RNA-targeting therapeutics for the c.607G>A variant of GNAO1-associated encephalopathy.